

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Alchem Ltd</u> <hr/> (Last) (First) (Middle) KARAIISKAKI 6 CITY HOUSE <hr/> (Street) LIMASSOL G4 3032 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Osmotica Pharmaceuticals plc [OSMT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/13/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	01/13/2020		P		1,250,000	A	\$5 ⁽¹⁾	22,485,297	D	
Ordinary Shares								1,182,243	I	By Self as Sole Manager of Orbit Co-Invest A-1 LLC ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person * <u>Alchem Ltd</u> <hr/> (Last) (First) (Middle) KARAIISKAKI 6 CITY HOUSE <hr/> (Street) LIMASSOL G4 3032 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person *

[Orbit Co-Invest A-1 LLC](#)

(Last) (First) (Middle)

895 SAWYER ROAD

(Street)

MARIETTA GA 30062

(City) (State) (Zip)

Explanation of Responses:

1. The acquisition of Ordinary Shares reported on this Form 4 (the "Acquired Shares") was made pursuant to an underwritten public offering of Ordinary Shares by Osmotica Pharmaceuticals plc (the "Issuer"). In connection with such offering, the underwriters reimbursed the Issuer for any discounts and commissions payable by the Issuer with respect to the Acquired Shares (the "Discount"). The Issuer in turn paid a fee equal to the amount of the Discount to Alchem Limited totaling \$406,250 (the "Fee"), or \$0.325 per share. The \$5.00 per share price does not reflect payment of the Fee to Alchem Limited.

2. Represents shares of the Issuer held by Orbit Co-Invest A-1 LLC. Alchem Limited is the sole manager of Orbit Co-Invest A-1 LLC. As a result, Alchem Limited may be deemed to share voting and investment power with respect to the shares held by Orbit Co-Invest A-1 LLC. Alchem Limited disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

[Alchem Limited By: /s/
Georgios Filippou, Director](#) [01/15/2020](#)

[Orbit Co-Invest A-1 LLC, by
Alchem Limited, its sole
manager By: /s/ Georgios
Filippou, Director](#) [01/15/2020](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.